<DOC>
	<DOCNO>NCT01095003</DOCNO>
	<brief_summary>The increase use anthracyclines taxanes adjuvant , neoadjuvant first-line metastatic setting , lead raise patient present metastatic breast cancer treatment agent . Options treatment patient progress anthracycline taxane limit . The high level in-vitro synergy vinflunine combine 5-fluorouracil ( 5-FU ) together good tolerance encouraging response rate observe combine IV vinflunine oral capecitabine make promising combination investigate phase III trial . This phase III trial evaluate effectiveness safety profile combination treatment patient advance breast cancer previously treat resistant anthracycline taxane resistant .</brief_summary>
	<brief_title>Trial Vinflunine Plus Capecitabine Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>female patient 21 year age old histologically/cytologically confirm carcinoma breast document locally recurrent metastatic disease amenable curative surgery radiotherapy either one , two three prior chemotherapy regimens prior treatment include anthracycline taxane patient longer candidate drug measurable nonmeasurable disease accord RECIST 1.1 Karnofsky performance score least 70 % adequate haematological , hepatic renal function ECG without clinically relevant abnormality know clinical evidence brain metastasis leptomeningeal involvement pulmonary lymphangitis symptomatic pleural effusion serious , concurrent uncontrolled medical disorder history second primary malignancy preexist motor/sensory peripheral neuropathy know history HIV infection prior therapy capecitabine and/or vincaalkaloids history severe hypersensitivity vinca alkaloid and/or fluoropyrimidine contra indication drug know suspected dihydropyrimidine dehydrogenase ( DPD ) deficiency pregnancy breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>